Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21
                        st
                         century

GEKID Cancer Survival Workgroup

doi:10.3324/haematol.2016.157768

Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 ^st century

GEKID Cancer Survival Workgroup

Institute of Social Medicine and Epidemiology

3 Citations (Scopus)

Abstract

Population-level survival has increased for a number of hematologic malignancies.1–3 Multiple myeloma, in particular, has seen improved survival both in clinical trials4–8 and on the population level.3,9–11 However, it is not known whether the changes in survival for myeloma have extended to other, less common plasma cell or plasmacytoid malignancies such as lymphoplasmacytic lymphoma (LPL, includes Waldenström’s macroglobulinemia (WM)), plasma cell leukemia (PCL), and solitary plasmacytoma (SP). Only a few population level studies of survival are available on LPL,12,13 PCL,14,15 and SP,16 with little information on changes in survival in the past decade.

...

Original language	English
Journal	Haematologica
Volume	102
Issue number	6
Pages (from-to)	229-232
Number of pages	4
ISSN	0390-6078
DOIs	https://doi.org/10.3324/haematol.2016.157768
Publication status	Published - 01.01.2017

Research Areas and Centers

Research Area: Center for Population Medicine and Public Health (ZBV)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3324/haematol.2016.157768

Cite this

@article{8532bac44390493698ed1fd720f02e4b,

title = "Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 st century",

abstract = "Population-level survival has increased for a number of hematologic malignancies.1–3 Multiple myeloma, in particular, has seen improved survival both in clinical trials4–8 and on the population level.3,9–11 However, it is not known whether the changes in survival for myeloma have extended to other, less common plasma cell or plasmacytoid malignancies such as lymphoplasmacytic lymphoma (LPL, includes Waldenstr{\"o}m{\textquoteright}s macroglobulinemia (WM)), plasma cell leukemia (PCL), and solitary plasmacytoma (SP). Only a few population level studies of survival are available on LPL,12,13 PCL,14,15 and SP,16 with little information on changes in survival in the past decade....",

author = "{GEKID Cancer Survival Workgroup} and Janick Weberpals and Dianne Pulte and Lina Jansen and Sabine Luttmann and Bernd Holleczek and Alice Nennecke and Meike Ressing and Alexander Katalinic and Maximilian Merz and Hermann Brenner",

year = "2017",

month = jan,

day = "1",

doi = "10.3324/haematol.2016.157768",

language = "English",

volume = "102",

pages = "229--232",

journal = "Haematologica",

issn = "0390-6078",

number = "6",

}

TY - JOUR

T1 - Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21 st century

AU - GEKID Cancer Survival Workgroup

AU - Weberpals, Janick

AU - Pulte, Dianne

AU - Jansen, Lina

AU - Luttmann, Sabine

AU - Holleczek, Bernd

AU - Nennecke, Alice

AU - Ressing, Meike

AU - Katalinic, Alexander

AU - Merz, Maximilian

AU - Brenner, Hermann

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Population-level survival has increased for a number of hematologic malignancies.1–3 Multiple myeloma, in particular, has seen improved survival both in clinical trials4–8 and on the population level.3,9–11 However, it is not known whether the changes in survival for myeloma have extended to other, less common plasma cell or plasmacytoid malignancies such as lymphoplasmacytic lymphoma (LPL, includes Waldenström’s macroglobulinemia (WM)), plasma cell leukemia (PCL), and solitary plasmacytoma (SP). Only a few population level studies of survival are available on LPL,12,13 PCL,14,15 and SP,16 with little information on changes in survival in the past decade....

AB - Population-level survival has increased for a number of hematologic malignancies.1–3 Multiple myeloma, in particular, has seen improved survival both in clinical trials4–8 and on the population level.3,9–11 However, it is not known whether the changes in survival for myeloma have extended to other, less common plasma cell or plasmacytoid malignancies such as lymphoplasmacytic lymphoma (LPL, includes Waldenström’s macroglobulinemia (WM)), plasma cell leukemia (PCL), and solitary plasmacytoma (SP). Only a few population level studies of survival are available on LPL,12,13 PCL,14,15 and SP,16 with little information on changes in survival in the past decade....

UR - http://www.scopus.com/inward/record.url?scp=85020182017&partnerID=8YFLogxK

U2 - 10.3324/haematol.2016.157768

DO - 10.3324/haematol.2016.157768

M3 - Letters

C2 - 28280077

AN - SCOPUS:85020182017

SN - 0390-6078

VL - 102

SP - 229

EP - 232

JO - Haematologica

JF - Haematologica

IS - 6

ER -